摘要
目的探讨CD8及Foxp3在恶性黑色素瘤组织中的表达与PD-1抑制剂治疗的近远期疗效的关系。方法选取江西省肿瘤医院2019年1月至2021年6月经PD-1抑制剂治疗的恶性黑色素瘤患者,通过免疫组化检测CD8及Foxp3在恶性黑色素瘤组织中的表达,分析其与恶性黑色素瘤PD1抑制剂疗效及患者预后的相关性。结果CD8阳性表达患者疾病控制效果及无进展生存期显著好于阴性患者(P<0.05)。Foxp3阳性表达者疾病控制率及无进展生存期明显低于阴性表达者(P<0.05)。CD8的表达和PD-1抑制剂的应用之间为正向关系,而Foxp3的表达则与其之间为负反馈关系,且有统计学差异(P<0.05)。结论CD8及Foxp3在恶性黑色素瘤组织中的表达与PD-1抑制剂的近远期疗效密切相关。
Objective To study the expression of CD8 and Foxp3 in malignant melanoma and its relationship with efficacy of PD-1 inhibitors.Methods Malignant melanoma patients treated with PD-1 inhibitors was selected,and the expression of CD8 and Foxp3 in malignant melanoma was detected by immunohistochemical testing,and its relationship with efficacy of PD-1 inhibitors and prognosis were analyzed.Results The disease control effect and progression free survival time of CD8 positive patients were significantly better than those of CD8 negative patients(P<0.05).The disease control rate and progression free survival time of Foxp3 positive patients were significantly lower than those of negative expression patients(P<0.05).There was positive relationship between the expression of CD8 and the application of PD-1 inhibitors,while the expression of Foxp3 had negative relationship with application of PD-1 inhibitors,and there had statistical difference(p-value<0.05).Conclusion The expression of CD8 and Foxp3 in malignant melanoma tissue is closely related to the short-term and long-term efficacy of PD-1 inhibitors.
作者
邹平安
陶志伟
杨峥旭
刘哲
廖建玉
ZOU Ping'an;TAO Zhiwei;YANG Zhengxu(Jiangxi Cancer Hospital,Nanchang,330006)
出处
《实用癌症杂志》
2023年第12期2082-2084,2086,共4页
The Practical Journal of Cancer
